MBX Biosciences, Inc.
NEWS
MBX Biosciences secured $115 million in Series B financing to advance its pipeline of Precision Endocrine Peptides for endocrine disorders.
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Onxeo, Amydis, eFFECTOR Therapeutics, Freenome, Urovant Sciences and others all added new guidance and perspectives to their C-suite this week.
JOBS
IN THE PRESS